Investor profile

Stanley Freeman Druckenmiller

Chairman, Blue Meridian Partners

Stanley Freeman Druckenmiller is an American investor and philanthropist. He founded Duquesne Capital in 1981, ran the fund for three decades, and closed it in 2010 to operate the Duquesne Family Office, where he serves as chairman, chief executive officer, and chief investment officer. Earlier in his career he was lead portfolio manager of George Soros’s Quantum Fund and helped generate the famed 1992 short‑selling profit on the British pound. He is known for achieving roughly 30% annual returns without a losing year.

Druckenmiller chairs the board of Harlem Children’s Zone, serves on the board of Memorial Sloan Kettering Cancer Center, and has led Blue Meridian Partners as chair and founding chair emeritus. He lives in New York City.

Current roles include Chairman at Blue Meridian Partners, Chairman & Chief Executive Officer at Duquesne Family Office LLC, Chairman Emeritus of the Board at Harlem Children’s Zone, Board Member at Memorial Sloan Kettering Cancer Center, Board Member at Environmental Defense Fund, Investment Committee Member at Bowdoin College, and Co‑founder & Board Member at Kasparov Chess Foundation. Based in New York, New York, United States.

Earlier roles include Founder, Chairman & President at Duquesne Capital Management, Lead Portfolio Manager, Quantum Fund at Soros Fund Management (Quantum Fund), and Managing Director; Chief Investment Officer at Soros Fund Management. Personal investments include Commonwealth Fusion Systems, Q.ANT, and Curative (Curative Health Insurance Company).

Portfolio
4
Disclosed capital
$1B
Active roles
7
Career since
1977

Career

Career history and operating roles assembled from public biographies and company records.

  • Present
    Chairman & Chief Executive Officer
    CurrentExecutive
    D
    Duquesne Family Office LLC
  • Present
    Chairman Emeritus of the Board
    CurrentBoard
    H
    Harlem Children’s Zone
  • Present
    Chairman
    CurrentBoard
    B
    Blue Meridian Partners

Portfolio Companies

Publicly attributed investments compiled from reporting and company disclosures.

  • C
    Cellares
    Series DJan 28, 2026
    Reported round size$257M
  • C
    Curative (Curative Health Insurance Company)
    Series BDec 2, 2025
    Reported round size$150M+
  • Q
    Q.ANT
    Series A (second closing)Oct 30, 2025
    Amount not publicundisclosed

Sources

Underlying source material used to support the profile and portfolio entries.